Partial MAGL Inhibition Preserved Repeated Pain-Response and Gastric Benefits in Mice

A mouse study found that repeated lower-dose JZL184 preserved antinociceptive and gastroprotective effects that became tolerant under higher-dose regimens. The result supports a dose-dependent experimental window, not a validated human treatment schedule.

Two disease-related models were used

Researchers examined neuropathic pain after sciatic nerve constriction and gastric hemorrhage induced by a nonsteroidal anti-inflammatory drug. JZL184 inhibits MAGL and thereby alters endogenous cannabinoid signaling. It is not THC or an ordinary cannabis extract.

Behavioral and receptor findings agreed across doses

Repeated higher doses reduced brain CB1 density and function and produced tolerance to the measured beneficial effects. Lower repeated doses maintained the effects and preserved the reported receptor measurements. Dose therefore changed both the functional outcome and the molecular adaptation pattern.

Cross-tolerance and withdrawal comparisons added limits

Higher repeated doses, but not lower doses, produced cross-tolerance to common THC effects and findings in a rimonabant-precipitated withdrawal model. These were finite-duration mouse experiments. Absence of a detected effect at the lower regimen does not establish safety at every duration, dose or endpoint.

The study supports investigating partial rather than maximal enzyme inhibition. It does not identify a human dose, establish treatment for neuropathic pain or recommend a strategy for preventing stomach injury. The compound, model and repeated-treatment conditions define the finding.

Related: interpreting cannabis tolerance claims.

Research cited

Kinsey SG; Wise LE; Ramesh D; Abdullah R; Selley DE; Cravatt BF; Lichtman AH. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. The Journal of pharmacology and experimental therapeutics (2013). doi:10.1124/jpet.112.201426. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us